# Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

> **NCT01465464** · PHASE3 · TERMINATED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 888 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Orantinib (TSU-68)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01465464
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2014-06
- **Final completion:** 2014-11
- **Target enrollment:** 888 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465464, "Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01465464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*